Company
QIAGEN
NYSE: QGEN
Venlo, Netherlands-headquartered molecular diagnostics company operating since 1984; its QIAstat-Dx syndromic PCR platform already runs respiratory, gastrointestinal and meningitis/encephalitis panels in more than 100 countries.
2 stories
Regulatory News has published 2 stories about QIAGEN between 1 October 2026 and 6 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 6 October 2026.
This page is generated from Regulatory News’ editorial coverage of QIAGEN. It is not an advertisement.
On the record
- Company
- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)
- Headquarters
- Venlo, Netherlands (operational headquarters in Hilden, Germany)
- Founded
- 1984, Düsseldorf — by scientists from Heinrich Heine University
- Regulator
- U.S. Food and Drug Administration (CDRH)
- Latest milestone
- FDA 510(k) clearance, QIAstat-Dx BCID GN Plus AMR Panel
Each line is taken from the most recent story of ours that states it.
